NICE Committee Reverses Policy on Pfizer’s Sutent for Renal Cancer

Drug Industry Daily
A A
A UK advisory board recommends Pfizer’s Sutent as a first-line treatment for certain renal cancer patients, reversing an earlier decision on the drug.

To View This Article:

Login

Subscribe To Drug Industry Daily